Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

New viable therapeutic strategy found for ER+ breast cancer

Researchers say they have found a viable new therapeutic strategy for estrogen receptor-positive (ER+) breast cancer, even cancers that are resistant to current standard of care treatments.

31 Mar 2020

Potential new method of breast cancer treatment using androgen receptor

Scientists may have discovered a new therapeutic approach to treat ER+ breast cancer using androgen receptor-stimulating drugs.

31 Mar 2020

YAP signal pathway plays a vital role in the onset of head-and-neck cancer

Joint research between Kobe University and National Hospital Organization Kyushu Cancer Center has revealed that mice with mutations in the YAP signal pathway develop head-and-neck cancer over an extremely short period of time (world's fastest cancer onset mouse model), indicating that this pathway plays a crucial role in the onset of these cancers.

25 Mar 2020

Study provides new insight into neurofibromin-deficient ER+ breast cancer

An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.

5 Mar 2020

How does the intestine heal?

The intestine is an amazing organ in multiple ways, not least of which is its capacity to heal itself even when it is injured or damaged. Finally, a study by researchers at Dana-Farber Cancer Institute, published in the journal Cell Stem Cell shows how intestinal stem cells keep their number constant to renew the intestinal lining as and when it is required.

20 Feb 2020

Cancer-fighting compound reduces fat in obese mice

Eric Prossnitz, PhD, and his team hope to help 93 million obese Americans fight their fat.

6 Feb 2020

Estrogen plays a role in expansion of liver metastases in non-sex-specific cancers

It is known that the tumor microenvironment plays an important role in the progression of cancer. But could estrogen present in this microenvironment facilitate the growth of liver metastases in women affected by colon, pancreatic and lung cancers?

17 Jan 2020

Major genetic study provides most comprehensive map of breast cancer risk variants to date

A major international study of the genetics of breast cancer has identified more than 350 DNA 'errors' that increase an individual's risk of developing the disease. The scientists involved say these errors may influence as many as 190 genes.

7 Jan 2020

Discovery could pave way for new breast cancer drugs

Eric Prossnitz, PhD, hopes to help many of the 12% of American women who are projected to be diagnosed with breast cancer in their lifetimes.

7 Jan 2020

10-year results from clinical trial of extended letrozole therapy for women with HR+ breast cancer

In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.

12 Dec 2019

Discovery of novel mechanism by which certain breast cancers can metastasize

Researchers from the Baylor College of Medicine and Harvard Medical School have found a novel mechanism to explain the resistance of certain breast cancers that spread in the major organs of the body. They hope that this would help develop new therapeutic strategies to treat the cancer.

12 Dec 2019

Anastrozole can be preventive drug-of-choice for women with high breast cancer risk

The Queen Mary University of London professor leading an international breast cancer study says anastrozole - rather than tamoxifen - should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.

12 Dec 2019

Drug-light combination could offer better control over CAR T-cell treatments

Bioengineers at the University of California San Diego are a step closer to making CAR T-cell therapy safer, more precise and easy to control.

15 Oct 2019

Study highlights practice patterns and factors associated with prognosis of male breast cancer

A recent analysis reveals that treatment of male breast cancer has evolved over the years. In addition, certain patient-, tumor-, and treatment-related factors are linked with better survival. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

7 Oct 2019

Understanding treatment and prognosis of male breast cancer

October is Breast Cancer Awareness Month, an annual campaign to raise awareness about the potentially-fatal disease. Breast cancer is known as an illness that affects mostly women, but about 1 percent of all breast cancers affect men, too.

7 Oct 2019

Roswell Park receives more than $15 million in grants for cancer research

Roswell Park Comprehensive Cancer Center researchers have received more than a dozen recent grant awards totaling more than $15.4 million.

14 Aug 2019

Scientists use AI to recognize patterns in breast cancer

Scientists have used artificial intelligence to recognize patterns in breast cancer - and uncovered five new types of the disease each matched to different personalized treatments.

2 Aug 2019

Targeted breast cancer therapy shows 'encouraging' results

Researchers have developed a targeted therapy that may significantly increase the survival of pre-menopausal women with advanced breast cancer

3 Jun 2019

Targeted therapy plus hormone therapy improves survival in premenopausal patients with advanced HR+ breast cancer

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2019